Physician profile
Michelle Hoffmann
NPI 1033319553
$741.01
in general payments reported to CMS, 2019-2025
11 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $390 · 2024: $21.48 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $248.44 | 2022-2023 | Caplyta |
| Merz North America, INC. | $107.14 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $106.89 | 2022-2023 | Rexulti, Abilify Maintena |
| Corium, LLC | $61.11 | 2023 | Azstarys |
| Abbvie INC. | $53.61 | 2023 | |
| Alkermes, INC. | $49.27 | 2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $39.30 | 2022-2023 | Spravato |
| Gilead Sciences, INC. | $21.48 | 2024 | |
| Sunovion Pharmaceuticals INC. | $20.09 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.02 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $13.66 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.